Literature DB >> 12875353

Weighing risks and benefits in treating the individual patient.

John C Sinclair1.   

Abstract

Treatments may cause both benefits and harms. In such cases, the size of the benefit (indicated by the NNT to prevent one target event) needs to be weighed against the harms. One way of doing this is to estimate a threshold NNT, based on the attributable risks of the adverse events and their RVs compared with the importance of the target event prevented. By comparing the NNT at a given baseline risk with the threshold NNT, a critical baseline risk is identified above which treatment benefits are expected to outweigh harms. The assignment of RVs to benefits and harms of treatment is a necessary and crucial step in making a treatment recommendation. Consideration of the determinants of the threshold NNT may assist clinicians and parents in the explicit use of underlying values when making treatment decisions.

Entities:  

Mesh:

Year:  2003        PMID: 12875353     DOI: 10.1016/s0095-5108(03)00023-x

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  4 in total

1.  Predictive models for severe intraventricular hemorrhage in preterm infants.

Authors:  R Singh; P F Visintainer
Journal:  J Perinatol       Date:  2014-10       Impact factor: 2.521

2.  Methodological issues in the design and analyses of neonatal research studies: Experience of the NICHD Neonatal Research Network.

Authors:  Abhik Das; Jon Tyson; Claudia Pedroza; Barbara Schmidt; Marie Gantz; Dennis Wallace; William E Truog; Rosemary D Higgins
Journal:  Semin Perinatol       Date:  2016-06-22       Impact factor: 3.300

3.  A predictive model for SIVH risk in preterm infants and targeted indomethacin therapy for prevention.

Authors:  Rachana Singh; Samuel V Gorstein; Frank Bednarek; Joseph H Chou; Elisabeth C McGowan; Paul F Visintainer
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

4.  Stopping guidelines for an effectiveness trial: what should the protocol specify?

Authors:  Jon E Tyson; Claudia Pedroza; Dennis Wallace; Carl D'Angio; Edward F Bell; Abhik Das
Journal:  Trials       Date:  2016-05-10       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.